Prima BioMed, Macfarlane Burnet Institute for Medical Research and Public Health deal

Under a two-year deal, the institute granted PRR first rights to IP related to ex vivo cell therapies for cancer. The agreement is renewable for an additional two years. If PRR exercises its right to ...